Leap Thereutics报告了DeFiance研究B部分的最终结果，即Sirexatamab的2期研究，该研究在既往接受过一种晚期疾病系统治疗的MSG CRC患者中进行

Sirexatamab demonstrated statistically significant improvement in PFS and OS in DKK1-high population

Increasing DKK1 levels further improved PFS, OS, and ORR advantage for the Sirexatamab Arm

Leap to continue supporting development of sirexatamab in DKK1-high CRC patients

CAMBRIDGE, Mass., Oct. 20, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced final results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. The final clinical results were presented on behalf of the DeFianCe study investigators by Zev Wainberg, MD, Professor of Medicine and Co-Director of the GI Oncology Program at UCLA in a Mini Oral session at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany.